ADAPTIVE BIOTECHNOLOGIES (ADPT)       7.12  +0.27 (+3.94%)

7.12  +0.27 (+3.94%)

US00650F1093 - Common Stock - After market: 7.12 0 (0%)

ADAPTIVE BIOTECHNOLOGIES7.12

NASDAQ:ADPT (9/30/2022, 7:05:35 PM)+0.27 (+3.94%)

After market: 7.12 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Life Sciences Tools & Services
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-03 2022-08-03/amc Earnings (Next) 11-01 2022-11-01
Ins Owners 2.46% Inst Owners 95.45%
Market Cap 1.02B Shares 142.87M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 78.67
IPO 06-27 2019-06-27

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ADPT Daily chart

Company Profile

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 858 full-time employees. The company went IPO on 2019-06-27. The firm is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). The company uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. The company also focuses on developing immune-mediated therapies in oncology and other disease areas.

Company Info

ADAPTIVE BIOTECHNOLOGIES

1165 Eastlake Ave E

Seattle WASHINGTON 98102

P: 12066590067.0

CEO: Chad Robins

Employees: 858

Website: https://www.adaptivebiotech.com

ADPT News

News Image20 days ago - Adaptive BiotechnologiesAdaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million

SEATTLE, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates...

News Imagea month ago - Adaptive BiotechnologiesAdaptive Biotechnologies to Participate in the Morgan Stanley Global Healthcare Conference

SEATTLE, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage...

News Image2 months ago - Adaptive BiotechnologiesAdaptive Biotechnologies Reports Second Quarter 2022 Financial Results

SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage...

News Image2 months ago - Adaptive BiotechnologiesAdaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring Minimal Residual Disease in Diffuse Large B-Cell Lymphoma

clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in DLBCL...

News Image3 months ago - Adaptive BiotechnologiesAdaptive Biotechnologies to Report Second Quarter of 2022 Financial Results on August 3, 2022

SEATTLE, July 08, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial-stage biotechnology company that aims to...

News Image4 months ago - Adaptive BiotechnologiesAdaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease

T-Detect Lyme enables patients and healthcare providers to detect early Lyme disease with greater sensitivity than leading antibody tests...

ADPT Twits

Here you can normally see the latest stock twits on ADPT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example